Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 14 Apr 2025

Best evidence summary for preventing and preventing epidermal growth factor receptor inhibitors induced paronychia in cancer patients

in Cancer Molecular Targets and Therapeutics

Kexuan Li
Xiuyue Qiu
Jiayu Zhang
Yingshuyi Zhou
Youfen Fan

Frontiers in Oncology

doi 10.3389/fonc.2025.1555114

903 views

Case Report

Published on 14 Apr 2025

Unexpected outcomes of tislelizumab treatment in thoracic metastasis of malignant phyllodes tumors: a case report and literature review

in Cancer Molecular Targets and Therapeutics

Yihao Liu
Zhixuan Duan
Minghui Liu
Yongwen Li
Min Wang
Jun Chen
Honglin Zhao

Frontiers in Oncology

doi 10.3389/fonc.2025.1535653

1,019 views

Original Research

Published on 11 Apr 2025

PITX1 as a grading, prognostic and tumor-infiltrating immune cells marker for chondrosarcoma: a public database-based immunoassay and tissue sample analysis

in Cancer Molecular Targets and Therapeutics

Zikun Huang
Dongchen Liu
Ying Zhang
Weiqing Lu
Lan Hu
Jinghao Zhang
Lei Xie
Shubiao Chen

Frontiers in Oncology

doi 10.3389/fonc.2025.1477649

804 views

Original Research

Published on 10 Apr 2025

NETs-related genes predict prognosis and are correlated with the immune microenvironment in osteosarcoma

in Cancer Molecular Targets and Therapeutics

Dawei Chu
Rui Huang
Jiandang Shi
Ruiqing Xu
Daihao Wei

Frontiers in Oncology

doi 10.3389/fonc.2025.1551074

721 views

Original Research

Accepted on 09 Apr 2025

Preparation of RGD-modified liposome encapsulated with shikonin and its targeted anti-melanoma effects

in Cancer Molecular Targets and Therapeutics

Hao Zhang
Ying Zhao
Tingting Chen
Xinliang Mao
Jiping Li
Li Fan
Min Li
Xianchun Wen

Frontiers in Oncology

doi 10.3389/fonc.2025.1573628

131 views

Original Research

Published on 08 Apr 2025

Lnc-CNNM3-DT as a protective factor in cervical cancer: regulation of LIAS expression and intracellular copper levels

in Cancer Molecular Targets and Therapeutics

Ying Yang
Xuehong Zhu
Dan Sun
Jiangtao Fan

Frontiers in Oncology

doi 10.3389/fonc.2025.1571788

781 views

Original Research

Published on 08 Apr 2025

FGFR3-TACC3 fusion gene promotes glioblastoma malignant progression through the activation of STAT3 signaling pathway

in Cancer Molecular Targets and Therapeutics

Yiming Li
Jianshen Liang
Xiude Ren
Jiahe Guo
Xisen Wang
Xuya Wang
Shengping Yu
Tao Li
Xuejun Yang

Frontiers in Oncology

doi 10.3389/fonc.2025.1560008

1,427 views

Review

Published on 08 Apr 2025

The biological role and molecular mechanism of transfer RNA-derived small RNAs in tumor metastasis

in Cancer Molecular Targets and Therapeutics

Haotian Dong
Chengyuan Ye
Xiaohan Ye
Jianing Yan
Guoliang Ye
Yongfu Shao

Frontiers in Oncology

doi 10.3389/fonc.2025.1560943

712 views

Case Report

Published on 07 Apr 2025

Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion

in Cancer Molecular Targets and Therapeutics

Nadja Ballin
Alexander Ott
Olga Seibel-Kelemen
Irina Bonzheim
Dominik Nann
Janina Beha
Stephan Spahn
Stephan Singer
Stephan Ossowski
Cristiana Roggia

Frontiers in Oncology

doi 10.3389/fonc.2025.1527484

1,135 views

Original Research

Published on 07 Apr 2025

WGCNA-ML-MR integration: uncovering immune-related genes in prostate cancer

in Cancer Molecular Targets and Therapeutics

Jing Lv
Yuhua Zhou
Shengkai Jin
Chaowei Fu
Yang Shen
Bo Liu
Menglu Li
Yuwei Zhang
Ninghan Feng

Frontiers in Oncology

doi 10.3389/fonc.2025.1534612

1,356 views

Review

Published on 07 Apr 2025

Intrathecal pemetrexed chemotherapy combined with systemic therapy in patients with non-small cell lung cancer and leptomeningeal metastases: a retrospective study

in Cancer Molecular Targets and Therapeutics

Wenjuan Zhong
Longqiu Wu
Zhengang Qiu
Wei Yu
Linfang Liu
Huaqiu Shi
Shugui Wu

Frontiers in Oncology

doi 10.3389/fonc.2025.1545174

1,121 views

Review

Published on 07 Apr 2025

Enhancing antitumor immunity: the role of immune checkpoint inhibitors, anti-angiogenic therapy, and macrophage reprogramming

in Cancer Molecular Targets and Therapeutics

Chong Zhang
Hua Wang
Xinying Li
Yuxin Jiang
Guoping Sun
Hanqing Yu

Frontiers in Oncology

doi 10.3389/fonc.2025.1526407

1,045 views

Review

Published on 01 Apr 2025

Advancements in research on the precise eradication of cancer cells through nanophotocatalytic technology

in Cancer Molecular Targets and Therapeutics

Changyang Yao
Chensong Zhang
Dongwei Fan
Xuanhe Li
Shaofa Zhang
Daoxin Liu

Frontiers in Oncology

doi 10.3389/fonc.2025.1523444

1,001 views

Original Research

Published on 31 Mar 2025

Identification of MAD2L1 as a novel biomarker for hepatoblastoma through bioinformatics and machine learning approaches

in Cancer Molecular Targets and Therapeutics

Ying He
Xiwei Hao
Bin Hu
Nan Xia
Chaojin Wang
Xin Chen
Huanyu Zhang
Yuhe Duan
Qinglong Ying
Qian Dong

Frontiers in Oncology

doi 10.3389/fonc.2025.1524714

814 views

Review

Published on 31 Mar 2025

The role and regulatory mechanism of lysosome associated protein transmembrane 4β in tumors

in Cancer Molecular Targets and Therapeutics

Yuteng Yang
Yumei Li
Yaqi Wang
Xi Chen
Yisong Yao
Dongxian Li
Guohua Yu
Xicheng Song

Frontiers in Oncology

doi 10.3389/fonc.2025.1552007

917 views

Case Report

Published on 28 Mar 2025

Case Report: Personalized diagnosis and treatment strategies for three cases of cancer of unknown primary based on molecular testing techniques

in Cancer Molecular Targets and Therapeutics

Yao Ding
Kexue Zhou
Kaiwen Fu
Xingyun Liao
Shuanglong Xiong
Chengxiang Yang
Mingyang Hu
Guanzhong Liang
Xianghua Zeng
Yongsheng Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1505271

921 views